Kiniksa Pharmaceuticals (KNSA)
Markets ARCALYST for recurrent pericarditis while advancing a cardiovascular-focused clinical pipeline.
$80.10
Pre-market+0.17 (+0.21%)
At close$79.93(+0.82%)
Something off on this page? Send us feedback.
Next report
Oct 27, 2026
in 54 days
EPS estimate
$0.39
Revenue estimate
$259.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$0.12$0.11$0.23$0.23$0.17$0.27$0.30Pending
Estimate−$0.06$0.02$0.18$0.33$0.29$0.18$0.30$0.39
Surprise−100.0%+450.0%+27.8%−30.3%−41.4%+50.0%+0.2%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$122.5M$137.8M$156.8M$180.9M$202.1M$214.3M$243.6MPending
Estimate$123.4M$131.9M$166.5M$197.1M$200.8M$206.1M$226.5M$259.6M
Surprise−0.7%+4.5%−5.8%−8.2%+0.7%+4.0%+7.6%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $0.39 | — | — |
| Jul 2026 | $0.30 | $0.30 | +0.2% |
| Apr 2026 | $0.18 | $0.27 | +50.0% |
| Feb 2026 | $0.29 | $0.17 | −41.4% |
| Oct 2025 | $0.33 | $0.23 | −30.3% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | $0.39 | — | — | $259.6M | — | — | — |
| Jul 28, 2026 | $0.30 | $0.30 | +0.2% | $226.5M | $243.6M | +7.6% | +1.9% |
| Apr 28, 2026 | $0.18 | $0.27 | +50.0% | $206.1M | $214.3M | +4.0% | −1.6% |
| Feb 24, 2026 | $0.29 | $0.17 | −41.4% | $200.8M | $202.1M | +0.7% | −1.7% |
| Oct 28, 2025 | $0.33 | $0.23 | −30.3% | $197.1M | $180.9M | −8.2% | −5.2% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||||||
| Jul 29, 2025 | |||||||
| Apr 29, 2025 | |||||||
| Feb 25, 2025 | |||||||
| Oct 29, 2024 | |||||||
| Jul 23, 2024 | |||||||
| Apr 23, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Oct 31, 2023 | |||||||
| Jul 25, 2023 | |||||||
| May 2, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 3, 2022 | |||||||
| May 3, 2022 | |||||||
| Feb 22, 2022 | |||||||
| Nov 1, 2021 | |||||||
| Aug 3, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 23, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Jul 30, 2020 | |||||||
| Apr 28, 2020 | |||||||
| Feb 26, 2020 | |||||||
| Oct 28, 2019 | |||||||
| Aug 12, 2019 | |||||||
| May 2, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 6, 2018 | |||||||
| May 24, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||